AstraZeneca & Daiichi Sankyo to jointly commercialise MOVANTIK in the US
AstraZeneca today announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for MOVANTIK™ (naloxegol) in the US, in line with the Company’s strategy of delivering value through its own development and commercial capabilities as well as through external collaboration.
AstraZeneca's Scientific Review Board to support clinical trial data transparency commitment
AstraZeneca today announced the creation of a Scientific Review Board that will act independently to assess requests from external researchers which include patient level data.
AstraZeneca's positive Phase III top-line results for PT003 from PINNACLE 1/2 studies in COPD
AstraZeneca today announced positive top-line results from the Phase III PINNACLE programme, which included two pivotal 24-week studies (PINNACLE 1 and PINNACLE 2) to investigate the potential of PT003 to improve lung function in patients with Chronic Obstructive Pulmonary Disease (COPD).
PEGASUS-TIMI 54 study results
PEGASUS-TIMI 54 study shows that long-term treatment with BRILINTA reduced thrombotic cardiovascular events in patients with a history of heart attack. Data from 21,000 patient study presented at American College of Cardiology 64th Annual Scientific Session and simultaneously published in New England Journal of Medicine
AstraZeneca to collaborate with key Singapore research organisations in heart failure
AstraZeneca today announced a two year collaboration with leading organisations in Singapore, including the Agency for Science, Technology and Research (A*STAR), National University Heart Centre, Singapore (NUHCS) and National University of Singapore, to support research into new therapies for heart failure.
AstraZeneca to participate in US FDA Endocrinologic and Metabolic Drugs Advisory Committee
AstraZeneca has announced it will participate in the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on 14 April 2015 to discuss the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial for ONGLYZA® (saxagliptin) and Kombiglyze® XR (saxagliptin and metformin HCI extended-release).
AstraZeneca completes rights acquisition to Actavis’ branded portfolio in US & Canada
AstraZeneca today announced that it has completed the transaction to acquire the rights to Actavis’ branded respiratory business in the US and Canada.
AstraZeneca to create stand-alone company for small molecule early-stage antibiotic R&D
In line with AstraZeneca’s strategy to sharpen its focus on three main therapy areas, the company is changing the structure of its small molecule early-stage anti-infectives research and development.
AstraZeneca and Orca Pharmaceuticals announce research collaboration
AstraZeneca and Orca Pharmaceuticals announce research collaboration to identify best-in-class RORγ inhibitors to treat auto-immune diseases.
US District Court: PULMICORT RESPULES® (budesonide inhalation suspension) patent litigation
AstraZeneca today announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 (“the ‘834 patent”), protecting PULMICORT RESPULES in the US, is invalid.
AstraZeneca PLC fourth quarter and full year results 2014
AstraZeneca's financial results for 2014 are in line with the upgraded Company guidance given with its third quarter 2014 results.
AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada
A new agreement strengthens AstraZeneca’s aclidinium respiratory franchise and adds immediate revenues with long-term growth potential.
AstraZeneca receives planning consent for new global R&D centre and corporate HQ in Cambridge
AstraZeneca today announced that Cambridge City Council has granted planning permission for the Company’s new global R&D centre and corporate headquarters in the City. The purpose built facility will be located on the Cambridge Biomedical Campus and will be home to approximately 2,000 employees.
AstraZeneca collaborates to use CRISPR for genome editing across its drug discovery platform
AstraZeneca today announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas.
MAA for gout treatment lesinurad accepted by European Medicines Agency
AstraZeneca today announced the European Medicines Agency has accepted the Marketing Authorisation Application (MAA) for lesinurad 200mg tablets.
Trial of AstraZeneca heart drug meets primary endpoint
Study shows that both 60mg and 90mg doses of AstraZeneca's BRILINTA® (BRILIQUE™ in the UK) demonstrate statistically significant reduction in major cardiovascular thrombotic events in patients with a history of heart attack.
MedImmune and Omnis Pharmaceuticals focus on development of oncolytic viruses
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals, a privately-held biotechnology company focused on the development of oncolytic viruses.
Lynparza™ approved in EU as first-in-class treatment for advanced BRCA-mutated ovarian cancer
AstraZeneca today announced that the European Commission (EC) has granted Marketing Authorisation for Lynparza™ (olaparib) capsules (400mg twice daily) as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete…
AstraZeneca & Amgen present results from Phase III AMAGINE-1 study evaluating brodalumab
First Presentation of Phase III Data From Brodalumab Psoriasis Program
MOVENTIG® approved in the European Union for opioid-induced constipation
First in class treatment approved for adult patients with opioid-induced constipation who have had an inadequate response to laxatives.
New drug application for IRESSA accepted by US Food and Drug Administration
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for IRESSA® (gefitinib) as a targeted monotherapy for the first line treatment of patients with advanced or metastatic epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC), as identified through a companion diagnostic test.
AstraZeneca and Lilly initiate pivotal clinical trial for patients with early Alzheimer’s
AstraZeneca and Eli Lilly and Company (Lilly) today announced enrolment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. They aim to enrol more than 1,500 patients in 15 countries.
AstraZeneca to collaborate with Cancer Research UK in screening for new cancer medicines
AstraZeneca and Cancer Research UK today announced that they have signed a memorandum of understanding through which Cancer Research UK drug discovery investigators would be given access to state-of-the-art drug discovery facilities at the new AstraZeneca MRC UK Centre for Lead Discovery to be built in Cambridge.
Amgen and AstraZeneca announce positive results from final trial of psoriasis treatment
Study met all primary endpoints against Stelara® (ustekinumab)and placebo. Three pivotal studies form the basis for global regulatory filings, planned for 2015.
Duaklir® Genuair® approved in the European Union for COPD
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).